AAAAAA
Results:
1-15
|
Results: 15
Authors:
Garcia, AA
Muggia, FM
Spears, CP
Jeffers, S
Silberman, H
Pujari, M
Koda, RT
Citation: Aa. Garcia et al., Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2 '-deoxyuridine and leucovorin, ANTI-CANC D, 12(6), 2001, pp. 505-511
Authors:
Hornreich, G
Schloss, C
Hoskins, WJ
Muggia, FM
Citation: G. Hornreich et al., Doxil-induced radiation recall: A cause for false-positive PET scan findings, GYNECOL ONC, 80(3), 2001, pp. 422-423
Authors:
Safra, T
Groshen, S
Jeffers, S
Tsao-Wei, DD
Zhou, LY
Muderspach, L
Roman, L
Morrow, CP
Burnett, A
Muggia, FM
Citation: T. Safra et al., Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin - Analysis of toxicities and predictors of outcome, CANCER, 91(1), 2001, pp. 90-100
Authors:
Safra, T
Groshen, S
Jeffers, S
Tsao-Wei, DD
Zhou, LY
Muderspach, L
Roman, L
Morrow, CP
Burnett, A
Muggia, FM
Citation: T. Safra et al., Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin - Analysis of toxicities and predictors of outcome, CANC CYTOP, 91(1), 2001, pp. 90-100
Authors:
Klein, P
Prolla, G
Wallach, R
Melamed, J
Muggia, FM
Citation: P. Klein et al., BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary, CANCER J, 6(3), 2000, pp. 188-190
Authors:
Moinpour, CM
Triplett, JS
McKnight, B
Lovato, LC
Upchurch, C
Leichman, CG
Muggia, FM
Tanaka, L
James, WA
Lennard, M
Meyskens, FL
Citation: Cm. Moinpour et al., Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial, PSYCHO-ONC, 9(4), 2000, pp. 340-354
Authors:
Muggia, FM
Brady, MF
Alvarez, R
Citation: Fm. Muggia et al., Maintenance chemotherapy in advanced ovarian cancer - Reply, J CL ONCOL, 18(8), 2000, pp. 1804-1805
Authors:
Muggia, FM
Braly, PS
Brady, MF
Sutton, G
Niemann, TH
Lentz, SL
Alvarez, RD
Kucera, PR
Small, JM
Citation: Fm. Muggia et al., Phase III randomized study of cisplatin versus paclitaxel versus cisplatinand paclitaxel in patients with suboptimal stage III or IV ovarian cancer:A gynecologic oncology group study, J CL ONCOL, 18(1), 2000, pp. 106-115
Authors:
Fleming, GF
Roth, BJ
Baker, SD
Sutton, GP
Look, KY
Muggia, FM
Fracasso, PM
McGuire, WP
Citation: Gf. Fleming et al., Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma - A gynecologic oncology group study, AM J CL ONC, 23(6), 2000, pp. 609-613
Authors:
Rosenthal, MA
Gruber, ML
Glass, J
Nirenberg, A
Finlay, J
Hochster, H
Muggia, FM
Citation: Ma. Rosenthal et al., Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme, J NEURO-ONC, 47(1), 2000, pp. 59-63
Authors:
Israel, VP
Garcia, AA
Roman, L
Muderspach, L
Burnett, A
Jeffers, S
Muggia, FM
Citation: Vp. Israel et al., Phase II study of liposomal doxorubicin in advanced gynecologic cancers, GYNECOL ONC, 78(2), 2000, pp. 143-147
Authors:
Muggia, FM
Safra, T
Jeffers, S
Garcia, A
Groshen, S
Citation: Fm. Muggia et al., Intraperitoneal therapy with fluoropyrimidines in the treatment of ovarianand gastrointestinal cancers, CUR CLIN ON, 2, 2000, pp. 213-223
Authors:
Muggia, FM
Citation: Fm. Muggia, Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced permeability and retention, CLIN CANC R, 5(1), 1999, pp. 7-8
Authors:
Koda, RT
Garcia, AA
Chatterjee, DJ
Li, WY
Parimoo, D
Jeffers, S
Rogers, M
Leichman, CG
Leichman, L
Wu, EY
Shetty, BV
Webber, S
Clendinnin, N
Muggia, FM
Citation: Rt. Koda et al., Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors, CANC CHEMOT, 43(6), 1999, pp. 489-496
Authors:
Muggia, FM
Speyer, JL
Citation: Fm. Muggia et Jl. Speyer, Doxorubicin-induced cardiomyopathy, N ENG J MED, 340(8), 1999, pp. 654-655
Risultati:
1-15
|